首页> 美国卫生研究院文献>Journal of Circulating Biomarkers >Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
【2h】

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types

机译:分析123种外周人类免疫细胞亚群:定义年龄和健康供体与癌症患者之间的年龄差异而在标准免疫细胞类型分析中未发现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recent advances in human immunology have led to the identification of novel immune cell subsets and the biological function of many of these subsets has now been identified. The recent US Food and Drug Administration approval of several immunotherapeutics for the treatment of a variety of cancer types and the results of ongoing immunotherapy clinical studies requires a more thorough interrogation of the immune system. We report here the use of flow cytometry-based analyses to identify 123 immune cell subsets of peripheral blood mononuclear cells. The use of these panels defines multiple differences in younger (< 40 years) vs. older (≥ 40 years) individuals and between aged-matched apparently healthy individuals and metastatic cancer patients, aspects not seen in the analysis of the following standard immune cell types: CD8, CD4, natural killer, natural killer-T, regulatory T, myeloid derived suppressor cells, conventional dendritic cells (DCs), plasmacytoid DCs and B cells. The use of these panels identifying 123 immune cell subsets may aid in the identification of patients who may benefit from immunotherapy, either prior to therapy or early in the immunotherapeutic regimen, for the treatment of cancer or other chronic or infectious diseases.
机译:人类免疫学的最新进展已导致鉴定新的免疫细胞亚群,并且现已鉴定出许多这些亚群的生物学功能。最近美国食品和药物管理局批准了几种用于治疗多种癌症的免疫疗法,并且正在进行的免疫疗法临床研究的结果要求对免疫系统进行更彻底的研究。我们在这里报告使用基于流式细胞仪的分析来识别外周血单核细胞的123个免疫细胞亚群。这些面板的使用定义了年轻(<40岁)与年长(≥40岁)个体以及年龄匹配的看起来健康的个体与转移性癌症患者之间的多重差异,这些方面在以下标准免疫细胞类型的分析中未见:CD8,CD4,自然杀手,自然杀手-T,调节性T,髓样来源的抑制细胞,常规树突状细胞(DC),浆细胞样DC和B细胞。这些鉴定123个免疫细胞亚群的方法的使用可以帮助鉴定在治疗之前或在免疫治疗方案的早期可受益于免疫疗法的患者,以治疗癌症或其他慢性或传染性疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号